2633 Stock Overview
Through its subsidiaries, develops, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Jacobson Pharma Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.76 |
| 52 Week High | HK$0.79 |
| 52 Week Low | HK$0.54 |
| Beta | 0.39 |
| 11 Month Change | 18.75% |
| 3 Month Change | 31.03% |
| 1 Year Change | 20.63% |
| 33 Year Change | 49.02% |
| 5 Year Change | -49.33% |
| Change since IPO | -54.76% |
Recent News & Updates
Recent updates
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03Shareholder Returns
| 2633 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 4.1% | -3.0% | -5.3% |
| 1Y | 20.6% | -8.3% | 11.3% |
Return vs Industry: 2633 exceeded the Hong Kong Pharmaceuticals industry which returned -8.3% over the past year.
Return vs Market: 2633 exceeded the Hong Kong Market which returned 11.3% over the past year.
Price Volatility
| 2633 volatility | |
|---|---|
| 2633 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 19.1% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2633 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2633's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 1,723 | Derek Sum | www.jacobsonpharma.com |
Jacobson Pharma Corporation Limited, through its subsidiaries, develops, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including gastrointestinal disorders, cardiovascular conditions, inflammatory and autoimmune diseases, multiple myeloma treatment, oncology, breast cancer therapy, central nervous system, respiratory, oral antidiabetics, musculo-skeletal, genito-urinary, anti-infectives, endocrine and metabolic, dermatological, and anti-allergics. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines; treasury services; and management services.
Jacobson Pharma Corporation Limited Fundamentals Summary
| 2633 fundamental statistics | |
|---|---|
| Market cap | HK$1.50b |
| Earnings (TTM) | HK$186.36m |
| Revenue (TTM) | HK$1.47b |
8.1x
P/E Ratio1.0x
P/S RatioIs 2633 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2633 income statement (TTM) | |
|---|---|
| Revenue | HK$1.47b |
| Cost of Revenue | HK$847.32m |
| Gross Profit | HK$620.48m |
| Other Expenses | HK$434.12m |
| Earnings | HK$186.36m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 21, 2024
| Earnings per share (EPS) | 0.094 |
| Gross Margin | 42.27% |
| Net Profit Margin | 12.70% |
| Debt/Equity Ratio | 29.4% |
How did 2633 perform over the long term?
See historical performance and comparison